key: cord-0795955-rw395dwo
authors: Konrath, Kylie M.; Liaw, Kevin; Wu, Yuanhan; Zhu, Xizhou; Walker, Susanne N.; Xu, Ziyang; Schultheis, Katherine; Chokkalingam, Neethu; Du, Jianqiu; Tursi, Nicholas J.; Moore, Alan; Purwar, Mansi; Reuschel, Emma L.; Frase, Drew; Sullivan, Matthew; Maricic, Igor; Andrade, Viviane M.; Iffland, Christel; Broderick, Kate E.; Humeau, Laurent M. P. F.; Smith, Trevor R.F.; Pallesen, Jesper; Weiner, David B.; Kulp, Daniel W.
title: Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection
date: 2021-04-28
journal: bioRxiv
DOI: 10.1101/2021.04.28.441474
sha: 2c4be91440aeae38d89f68f8d8914733d22f1ee0
doc_id: 795955
cord_uid: rw395dwo

Antibodies from SARS-CoV-2 vaccines may target epitopes which reduce durability or increase the potential for escape from vaccine-induced immunity. Using a novel synthetic vaccinology pipeline, we developed rationally immune focused SARS-CoV-2 Spike-based vaccines. N-linked glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and comprehensive in vitro screening, we incorporated glycans into the Spike Receptor-Binding Domain (RBD) and assessed antigenic profiles. We developed glycan coated RBD immunogens and engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicited potent neutralizing antibodies in guinea pigs, hamsters and multiple mouse models, including human ACE2 and human B cell repertoire transgenics. RBD nanoparticles encoding wild-type and the P.1 SARS-CoV-2 variant induced high levels of cross-neutralizing antibodies. Single, low dose immunization protected against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of novel, potent coronavirus vaccines.

antibodies ( Figure 3B ). However, both g3.2 and g5.1 (harboring three and five glycans, respectively) 115 bound well to nAbs and had reduced affinity for non-nAbs ( Figure 3B ). Since new non-nAbs may be 116 identified in the future, we focused the remaining experiments on the more glycosylated variants (i.e. 117 g5.1 over g3.2), since they are more likely to reduce accessibility to epitopes recognized by non-nAbs.

We observed similar immunogenicity from BALB/c mice immunized with wild-type (WT) RBD or g5.1 119 RBD ( Figure 3C ,3D). To investigate the difference in specificity of the RBD elicited responses, we 120 employed an ACE2 blocking assay[52] ( Figure 3E ). We observed that RBD g5.1 elicited significantly more vaccines, we genetically fused RBDs to a set of four different self-assembling scaffold proteins [38] [39] [40] 53 ] with a potent CD4-helper epitope(LS-3) to help enhance germinal center responses [54] . Tandem 129 repeats of RBD have been shown to improve neutralization titers by 10-100 fold [55] , thus we displayed 130 dimers of RBDs on some of our self-assembling scaffolds as well. We engineered nanoparticles using 131 our computational design methods [38] , resulting in display of 7, 14, 24, 48, 60, 120 or 180 RBDs ( Figure   132 4A). We rapidly screened 19 nanoparticles directly in vivo using a single mouse per construct at a single 133 low dose of 2µg. We observed that 14 of the 19 nanoparticles were immunogenic ( Figure 4B ). Strikingly, 134 rapid antibody responses were detected just 1 week after immunization with RBD g5.1 24mer, RBD 135 48mer and RBD g5.1 120mer ( Figure 4B ). In parallel, we expressed and purified nanoparticles in vitro.

In contrast to wild type RBD multimers, which we could not purify and were not more immunogenic 137 than RBD monomer ( Figure S3A ,S3B), we were able to purify nine glycan modified RBD multimers as 

we pursued a lethal challenge study ( Figure 5A ). B6.Cg-Tg(K18-ACE2)2Prlmn/J(K18-hACE2) mice express 156 human ACE2 on epithelial cells including in the airway [56, 57] and can be infected with SARS-CoV-2 immunogenicity at day 21 and observed pseudovirus neutralization titers prior to challenge in all vaccine 161 groups ( Figure S7 ). We also observed live SARS-CoV-2 virus neutralization titers above the limit of 162 detection for all three nanoparticle groups with mean ID50 of 451, 1028, and 921 for RBD g5.1 120mer 163 1µg, 5µg and RBD g5.1 24mer 5µg, respectively, compared to a mean ID50 of 29 of RBD monomer ( Figure   164 5B). The mice were infected with SARS-CoV-2 1x10 5 PFU/mouse intranasally and monitored for signs of 165 deteriorating health. We observed that mice immunized with nanovaccines had higher levels of protection 166 from weight loss( Figure 5C ). As expected, the naive group of animals reached 100% morbidity by day 6 167 and 1/10 animals survived in the RBD monomer group. In both RBD g5.1 120mer groups had 6/10 mice 168 survived the challenge. Strikingly, immunization with RBD g5.1 24mer provided full protection from a 169 lethal SARS-CoV-2 challenge ( Figure 5D ). All but one animal that survived had a live virus neutralization 170 titer of >100 and 12/15 of the mice that succumbed to infection did not have appreciable neutralization 171 titers ( Figure 5E ). We observed a significant correlation between live virus neutralization ID50 titer and 172 body weight loss ( Figure 5F ). Viral replication was reduced in nasal turbinates, lung tissue and brain tissue 173 for mice immunized with nanovaccines relative to RBD monomer or naïve animals ( Figure 5G ). Thus, the 174 DNA-launched nanovaccines can generate potent immunity that provides protection from challenge with 175 a single immunization at a low dose.

Enhanced immune responses to nanovaccines in translational vaccine models One major challenge for 178 the clinical translation of vaccines is preclinical modeling of human antibody responses to immunogens.

OmniMouse® have humanized immunoglobulin loci-transgenic with human V, D and J gene segments[60].

As a proof-of-concept, we immunized OmniMouse®(n=3) with three different SARS-CoV-2 nanoparticle 181 vaccines and measured increasing RBD-specific human antibodies in serum ( Figure 

We assessed RBD g5.1 24mer in Hartley guinea pigs (n=6) to examine intradermal vaccine delivery at 0.5, 187 5 and 10µg in comparison to RBD monomer at 10µg. In contrast to the RBD monomer immunized group, 188 we observed full seroconversion of RBD g5.1 24mer immunized animals at a dose of 5µg ( Figure 6D ). High 189 levels of neutralizing antibodies were obtained in the 10µg dose group (ID50 of 1840) ( Figure 6E ). In a 190 proof-of-concept study of RBD DLNPs prior to the development of RBD g5.1 24mer, we immunized Syrian

Golden hamsters (n=5) twice 3 weeks apart with 2µg and 10 µg of RBD monomer and RBD 48mer ( Figure   192 6F). The RBD nanoparticle immunized hamsters elicited higher antibody titers after both first and second 193 doses and produced neutralizing antibodies unlike the responses in the RBD monomer vaccine groups 194 ( Figure 6G ). To assess the biodistribution of anti-RBD IgG, we measured ultrafiltrated lung lavages and 195 found antibodies only in the RBD nanoparticle groups ( Figure 6H ). In summary, we demonstrate that the 196 DLNP vaccines provide enhanced immunogenicity in guinea pigs and hamsters. 

Viral glycan evolution results in antigenic changes with concomitant immune evasion. It has been 205 observed that for influenza, humoral immunity becomes restricted over time due to glycan additions [61] .

SARS-CoV-2 mutational variants may escape from antibody-mediated immunity. Glycan mutational 207 variants may begin to circulate given their large impact on antibody recognition of virus. Here, we provide 208 a map of possible glycan additions to the RBD of SARS-CoV-2 and their effect on a large series nAbs.

Interestingly, we find a glycan at position 458, 369, 450 and 441 can bind to human ACE2, but strongly 210 reduces binding to nAbs targeting the sites RBD-A, B, C and D respectively. We also show that addition of 211 glycans to RBD-based nanovaccines can improve expression, assembly and immunogenicity.

The synthetic DNA platform employed in this study can be leveraged for generation of enhanced 213 immunity, easier global distribution and rapid reformulation. New adaptive electroporation systems can 214 improve uptake of DNA plasmid by 500x [62] . In stark contrast to complex recombinant protein and RNA-215 based product development, DNA-based production and purification are extremely easy due to 216 availability of off the shelf commercial purification kits used widely in research laboratories. DNA vaccines 217 are also much more chemically and thermally stable allowing storage at room temperature for long 218 periods of time. These characteristics of the DNA platform allows for new vaccines to be developed at 219 breakneck speed and distributed to resource limited settings around the globe. SARS-CoV-2 vaccines require at least two doses [63, 64] . DNA vaccines often require higher vaccine doses 222 (25 µg in mice [41] and 5 mg in NHPs [65] ) and/or advanced delivery devices to drive sufficient 223 immunogenicity. Here, we observed strong immunogenicity and protection from bona fide SARS-CoV-2 224 challenge down to 1 µg. However, we did observe weight loss in 2/6 mice after challenge and low viral 225 titers in 2/4 mice sacrificed four days after challenge. Increasing the dose to 10µg or by prime-boosting 226 could improve on our results. In fact, our studies of DNA-launched nanoparticle vaccines in guinea pigs 227 and hamsters demonstrated greater immunogenicity than RBD monomer at a low dose of 10µg.

In comparison to other RBD nanoparticle systems, we have demonstrated significant improvements.

Recently, studies on two-component spike-based nanoparticle showed strong immunogenicity with 230 sporadic pseudovirus neutralization 2 weeks post prime [66, 67] . After 2 doses of the i53-50 RBD 231 nanoparticle vaccine, mice challenged with 1x10 5 PFU of a mouse-adapted non-lethal virus were observed 232 to have reduced viral replication [67] . SpyTag-coupled RBD nanoparticles induce binding but not 233 neutralizing antibodies 2-weeks post prime [68] [69] [70] [71] . An RBD-HR SpyTag nanoparticle was observed to 234 induce immunity after 2 doses which after challenge with 4x10 4 PFU authentic SARS-CoV-2 could reduce 235 viral load in the lungs [72] . Here, the DNA-launched glycan modified RBDs could be genetically fused with 236 four different nanoparticles scaffolds, the simple genetic fusion results in a single vaccine product that 237 could induce binding and neutralizing antibodies 1 week post prime immunization and induce CD8+ Tcells.

We created a more stringent test of immunity than most previous studies as we used authentic SARS-

CoV-2 virus with 2.5-fold higher amount of virus (1x10 5 PFU) in the challenge and a 10-fold more sensitive 240 viral detection assay. Further, vaccines studied in this model mostly utilize a prime and boost to achieve 241 protection (personal communication, Texas Biomed). In this model, our nanovaccines could induce 242 immunity that reduced viral replication and completely protected from death at a low single dose of 5µg.

From the data, there is an 82% chance of survival if mice have a live virus neutralization titer >100 prior 244 to challenge. Given the protective threshold for neutralizing antibodies that we observe, we expect that 245 the high levels of cross-reactivity neutralization to the B.1.1.7, B.1.351, P.1 SARS-CoV-2 variants generated 246 by our nanovaccine would protect in a similar lethal challenge. In addition, the P.1 RBD g5.1 nanoparticle 247 elicited high levels of cross-reactive antibodies which could be employed as a booster vaccine.

In conclusion, we have developed single-dose SARS-CoV-2 nanovaccine with a platform that can afford 249 rapid pre-clinical reconfiguration to address variants of concern and for clinical translation. 

For in vitro characterization, high Binding, 96-well Flat-Bottom, Half-Area Microplate (Corning) were 309 coated at 1 µg/mL 6x-His tag polyclonal antibody (Invitrogen) for >4 hours at ambient temperature and 310 blocked ≥1 hour with 5% milk/1x PBS/0.01% Tween-20 at 4°C. RBD transfection supernatant or 311 recombinant protein at 10 µg /mL was incubated for 1-2 hours at ambient temperature. Serial dilutions 312 of antibodies were made according to affinity and incubated on plate for 1-2 hours at ambient 313 temperature. Goat anti-Human IgG-Fc fragment cross-adsorbed antibody HRP conjugated (Bethyl Laboratories) secondary at a 1:10,000 dilution for 1 hour at ambient temperature. All dilutions except 315 coating were performed in 5% milk/1x PBS/0.01% Tween-20 and plates were washed with 1x PBS/0.05%

Tween-20 between steps. 1-Step™ Ultra TMB-ELISA Substrate Solution (Thermo Scientific) was incubated 317 on the plate for 10 minutes in the dark and then quenched with 1 M H2SO4. Absorbance of samples at 318 570 nm was subtracted from 450 nm for each well and background of blank wells were subtracted from 319 each well before analysis. Curves were analyzed in GraphPad Prism 8 with Sigmoidal, 4PL, X is 320 concentration and AUC.

For serology, plates were coated with 1 µg/mL 6x-His tag polyclonal antibody (Invitrogen) in 1x PBS for 6 322 hours at ambient temperature and blocked overnight with 0.5% NCS/5% Goat Serum/5% Milk/0.2% PBS-

T. 5x serial dilutions of sera were made starting at a 1:100 dilution and incubated on plate for 2 hours at 

In-vivo study was concluded with terminal blood, lung lavage and nasal wash collection. Lavage buffer was 444 prepared as PBS containing 100uM EDTA, 0.05% Sodium Azide, 0.05% Tween-20 and Protease Inhibitor.

Hamsters were euthanized by jugular exsanguination with intraperitoneal (IP) injection of 86.7mg/kg 446 pentobarbital sodium or overdose Isoflurane gas inhalation. Euthanized hamster was placed in supine 447 position and skin was disinfected using 70% Isopropyl alcohol. A longitudinal cut using scissors and blunt 448 dissection along the midline of the neck was performed to expose the trachea. An opening into the 449 exposed trachea was created by making a transverse, semilunar cut using #11 blade.

To collect nasal wash an 18ga blunt end needle was inserted toward the nose and gently proceeded 

Competition assay 521 96-well Flat-Bottom Half-Area plates (Corning) were coated at room temperature for 8 hours with 1 522 µg/mL 6x-His tag polyclonal antibody (PA1-983B, ThermoFisher), followed by overnight blocking with 523 blocking buffer containing 5% milk/1x PBS/0.01% Tween-20 at 4°C. The plates were then incubated with 524 RBD at 1 µg/mL at room temperature for 1-2 hours. Mouse Sera (BALB/c ,terminal bleeds, week 6, n=5 ) 525 either immunized with RBD-WT or RBD-gPenta was serially diluted 3-fold starting at 1:20 with dilution 526 buffer (5% milk/1x PBS/0.01% Tween-20 ) was added to the plate and incubated at room temperature for 527 1-2 hours. Plates were then washed and incubated at room temperature for 1 hour with ACE2-IgHu at a 528 constant concentration of 0.06µg/mL diluted with the dilution buffer. After being washed, the plates were 529 further incubated at room temperature for 1 hour with goat-anti human IgG-Fc fragment cross-adsorbed 530 Ab (A80-340P; Bethyl Laboratories) at a 1: 10,000 dilution, followed by addition of TMB substrates 531 (ThermoFisher), and then quenched with 1M H2SO4. Absorbances at 450nm and 570nm were recorded 532 with a BioTek plate reader. Four washes were performed between every incubation step using PBS and 533 0.05% Tween-20. The assay was performed in triplicates. The average absorbance of the lowest dilutions with saturating ACE2 signals was calculated to get a maximum ACE2 binding and no blocking. Each average 535 absorbance value was subtracted from the maximum to get an ACE2 blocking curve. The blocking titer is 536 defined as the reciprocal of the highest dilution where two consecutive dilutions have readings below 537 zero. The maximum area under the curve is determined by calculating the Area Under the Curve (AUC) of 538 full ACE2 binding without the competitor. The AUC of the competitor is then subtracted from the 539 maximum AUC which provides the area between the two curves (blocking area) and is a measure of ACE2 540 blocking. The fraction ACE2 blocking is defined as the fraction of the blocking area to the maximum AUC. Week Neutralization titer (ID

Week 2

Week 3 Week 4 1 µg 5 µg

Week 6

Week 8 

An interactive web-based dashboard to track COVID-19 757 in real time

Data, disease and diplomacy: GISAID's innovative 759 contribution to global health. Glob Chall

Functional assessment of cell entry and receptor 761 usage for SARS-CoV-2 and other lineage B betacoronaviruses

A pneumonia outbreak associated with a new coronavirus of probable 764 bat origin

Robust neutralizing antibodies to SARS-CoV-2 infection persist for 766 months

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2

Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting 771 the Spike Receptor-Binding Domain Compete for ACE2 Binding. mSphere

Rapid Generation of Neutralizing Antibody Responses in COVID-19

Evaluation of candidate vaccine approaches for MERS-CoV

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing 777 antibodies

CoV-AbDab: the Coronavirus Antibody Database

Potent neutralizing antibodies from COVID-19 patients define 781 multiple targets of vulnerability

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 785 spike

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 787 from disease in a small animal model

Neutralizing antibody responses to SARS-CoV-2 in a COVID-790 19 recovered patient cohort and their implications medRxiv

Discordance between Serum Neutralizing Antibody Titers and the 792 Recovery from COVID-19

Antibody-dependent enhancement and SARS-CoV-2 vaccines and 794 therapies

Stabilization of the gp120 V3 loop through hydrophobic 796 interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-797 1 envelope trimers

Structure-based design of native-like HIV-1 envelope trimers to silence 799 non-neutralizing epitopes and eliminate CD4 binding

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 801 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-802 neutralizing antibodies

Epitope-focused vaccine design against influenza A and B viruses

A stable trimeric influenza hemagglutinin stem as a broadly 806 protective immunogen

Influenza virus hemagglutinin stalk-based antibodies and 808 vaccines

Hemagglutinin-stem nanoparticles generate heterosubtypic 810 influenza protection

Introduction of neutralizing immunogenicity index to the rational design of 812 MERS coronavirus subunit vaccines

SARS-CoV-2 neutralizing antibody structures inform therapeutic 814 strategies

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 816 Receptor Binding Domain

Exploitation of glycosylation in enveloped virus pathobiology

Glycosylation as a tool for rational vaccine design

V2 loop glycosylation of the human immunodeficiency virus 822 type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors 823 and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site 824 antibodies

Glycosylations in the globular head of the hemagglutinin protein 826 modulate the virulence and antigenic properties of the H1N1 influenza viruses

Glycan shielding of the influenza virus 829 hemagglutinin contributes to immunopathology in mice

Antibody neutralization and escape by HIV-1

Influenza Antigen Engineering Focuses Immune Responses to a 834 Subdominant but Broadly Protective Viral Epitope

Hyperglycosylated stable core immunogens designed to present the CD4 837 binding site are preferentially recognized by broadly neutralizing antibodies

A DNA-Launched Nanoparticle Vaccine Elicits CD8(+) T-cell Immunity to 840

Nanoparticles target distinct dendritic cell populations according to 845 their size

Immunological basis for enhanced immunity of 847 nanoparticle vaccines

Immunogenicity of a DNA vaccine candidate for COVID-19

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell 851 Host Microbe

A highly conserved cryptic epitope in the receptor binding domains of 853 SARS-CoV-2 and SARS-CoV

Structural basis for the neutralization of SARS-CoV-2 by an antibody from 855 a convalescent patient

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of 857

Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity

Studies in humanized mice and convalescent humans yield a SARS-CoV-860 2 antibody cocktail

A noncompeting pair of human neutralizing antibodies block COVID-19 862 virus binding to its receptor ACE2

A human neutralizing antibody targets the receptor-binding site of SARS-864

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 866 antibody

Convergent antibody responses to SARS-CoV-2 in convalescent 868 individuals

Potent binding of 2019 novel coronavirus spike protein by a SARS 870 coronavirus-specific human monoclonal antibody

SARS-CoV-2 Assays To Detect Functional Antibody Responses That 873

Block ACE2 Recognition in Vaccinated Animals and Infected Patients

Nanoparticle vaccines. Vaccine

Incorporation of a Novel CD4+ Helper Epitope Identified from Aquifex 877 aeolicus Enhances Humoral Responses Induced by DNA and Protein Vaccinations

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, 880 and SARS

Development of an epithelium-specific expression cassette with 882 human DNA regulatory elements for transgene expression in lung airways

Lethal infection of K18-hACE2 mice infected with severe acute 885 respiratory syndrome coronavirus

Lethality of SARS-CoV-2 infection in K18 human angiotensin-887 converting enzyme 2 transgenic mice

Comparison of transgenic and adenovirus hACE2 mouse models 889 for SARS-CoV-2 infection

Knockout rats via embryo microinjection of zinc-finger nucleases. 891 Science

Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a 893 Temporal Pattern to a Glycan Limit

DNA vaccines: prime time is now

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Two-component spike nanoparticle vaccine protects macaques 903 from SARS-CoV-2 infection

Elicitation of Potent Neutralizing Antibody Responses by Designed 905

Protein Nanoparticle Vaccines for SARS-CoV-2. Cell

Mosaic nanoparticles elicit cross-reactive immune responses to 907 zoonotic coronaviruses in mice

Self-assembling nanoparticles presenting receptor binding domain and 909 stabilized spike as next-generation COVID-19 vaccines. bioRxiv

A platform incorporating trimeric antigens into self-assembling 911 nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher 912 neutralizing responses than spike alone

A COVID-19 vaccine candidate using SpyCatcher multimerization of the 914 SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody 915 responses

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD)

Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

On the Calculation of TCID50 for Quantitation of Virus Infectivity

A Bayesian view on cryo-EM structure determination

CTFFIND4: Fast and accurate defocus estimation from 924 electron micrographs